Hims & Hers Health, Inc.

Freedom Broker now recommends clients buy shares of Hims &amp; Hers Health, a telehealth company, in the wake of a recent dip. The mid-cap stock has lost 35% of its market value due to a canceled partnership with pharma giant Novo Nordisk, which alleges that Hims&nbsp;&amp; Hers put patient safety at risk through “deceptive” marketing and sold a knockoff version of its drug Wegovy. Despite this, Freedom Broker analysts think Hims &amp; Hers stock will bounce back quickly.&nbsp;

Freedom Broker says buy Hims & Hers after cancellation of tie-up with Novo Nordisk

Novo Nordisk A/S

Eli Lilly and Company

Innovent Biologics is the first company in China to mount a real challenge to pharmaceutical giants Novo Nordisk and Eli Lilly in the obesity market. The approval of its weight loss drug opens a new chapter in the rapidly growing Chinese market, where local manufacturers are seeking to squeeze out foreign leaders with their expensive GLP-1 injections. What will the increased competition lead to and should the makers of Ozempic and Mounjaro be wary of the Chinese threat?

China approves Ozempic's first domestic competitor. What do investors need to know?

AstraZeneca PLC

At least a dozen companies are looking for a way to reduce muscle mass loss when taking weight loss drugs

Eli Lilly is entering a market valued at $30 billion, can it beat the competition?

Apple Inc.

Tesla, Inc.

What to expect for investors in the U.S. stock market on June 23

Morning in New York: geopolitics could deter buyers

Novo Nordisk's market value has fallen by nearly $400 billion in the ten months of the recession

Novo Nordisk shares recovered after the collapse. What will happen to the company next?

Investors are hopeful that the company will be able to recover sales after the leadership change

Novo Nordisk regained its status as Europe's most valuable company on a day of falling markets

Danish drugmaker Novo Nordisk seeks new chief executive after share price slump

An activist investor has taken an interest in the manufacturer Ozempic. What is it known for?  

Rheinmetall AG

Musk had a fight with Trump: what it means for investors. Nvidia briefly regained the title of the world's most valuable company. Alphabet threatens to drop in value by a quarter. The defense company will enter the eurozone's largest index. Read about the main news from June 2 to June 6 in our review.&nbsp;

Highlights of the week: Musk and Trump spat, Nvidia gave back $1 trillion, tanks instead of Gucci

"In my entire life, I never dreamed that we would be talking about medicines that are providing hope for people like me who have struggled for years with being overweight or with obesity," famous TV host <strong>Oprah Winfrey</strong> <a href="https://people.com/celebrities-ozempic-wegovy-what-theyve-said-7104926">told</a>  magazine two and a half years after Novo Nordisk's weight-loss drug Wegovy hit the market. Currently, Wegovy and Zepbound, made by U.S.-based Eli Lilly, account for 95% of the obesity market. In the upcoming years, however, they may face over a dozen new competitors. Which companies should investors keep an eye on in the space?

The skinny on investing in the weight-loss drug market

Shares of Lexaria Bioscience, a company that transforms the delivery of other companies’ drugs using its patented technology, <a href="https://www.nasdaq.com/market-activity/stocks/lexx">fell</a> more than 6% on Tuesday, October 15, after it <a href="https://ir.lexariabioscience.com/news-events/press-releases/detail/271/lexaria-announces-5-million-registered-direct-offering">announced</a> a raise of around $5 million through a private placement.

Weight-loss market innovator Lexaria Bioscience drops after direct offering announced

Canadian biotech company Lexaria Bioscience has <a href="https://ir.lexariabioscience.com/news-events/press-releases/detail/259/positive-results-from-lexarias-molecular-characterization">announced</a> positive findings from a study that could potentially allow Denmark’s Novo Nordisk to reduce production costs for its type 2 diabetes and obesity drugs. The study revealed that Lexaria DehydraTECH-processed semaglutide is just as effective as the semaglutide that serves as the active ingredient in Novo Nordisk’s Ozempic injection pens and Rybelsus tablets, for which the Danish company paid about $1.8 billion back in 2020. Following this news, Lexaria stock rose more than 6% in after-hours trading on Monday. Over the last year, the share price has now tripled.